Press Release

October 30, 2026 To, To, Listing Operation Department Listing Compliance Department BSE Limited National Stock Exchange of India Limited Phiroze Jeejeebhoy Towers, Exchange Plaza, C-1, Block G, Bandra Kurla Dalal Street, Mumbai - 400001 Complex, Bandra (East), Mumbai - 400051 (Scrip Code: 544644) (SYMBOL: CORONA) Dear Sir / Madam, Sub.: Press Release Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find enclosed herewith the Press Release on Unaudited Financial Results of the Company for Q2 and half year ended on September 30, 2026. The press release is also being made available on the website of the Company at www.coronaremedies.com You are requested to take note of the above. Thanking you. Yours faithfully, For CORONA Remedies Limited Chetna Dharajiya Company Secretary and Compliance Officer Encl.: A/a PRESS RELEASE CORONA Remedies delivers highest ever Revenue with growth of 22% for Q2FY27 on Y-o-Y basis, 1.9x the IPM growth Ahmedabad, October 30, 2026: CORONA Remedies Limited, one of the fastest growing companies amongst Top 30 Indian pharmaceutical companies, has announced its unaudited financial result for quarter & half year ended September 30, 2026. Financial Performance Snapshot: Particulars (₹ in Cr) Q2FY27 Q2FY26 Y-o-Y (%) H1FY27 H1FY26 Y-o-Y (%) Revenue from Operations 441.2 361.1 22.2% 863.6 707.7 22.0% EBITDA 96.0 78.5 22.3% 189.1 148.2 27.5% EBITDA Margin (%) 21.7% 21.7% - 21.9% 20.9% - Profit After Tax* 60.3 52.3 15.3% 120.4 98.5 22.2% PAT Margin* (%) 13.7% 14.5% - 13.9% 13.9% - *PAT & PAT Margins were lower on account of higher depreciation & amortization charge for our newly commissioned facilities & acquisition of brands, from which revenue contribution are expected to build up over the coming quarters. Key Business Highlights:  Outpacing IPM Growth1: CORONA continues to be one of the fastest growing companies among Top 30 companies of IPM as per MAT Sep’26 1. CORONA has outperformed market by 1.9 times for MAT Sep’261. CORONA is at 14th rank in its Covered Market and at 26th rank in overall IPM.  Focus on brand building: CORONA now has 4 brands exceeding ₹ 100 crores in annual sales, including 1 brand crossing ₹ 200 crores as per MAT Sep’26 1.  Operational excellence and disciplined execution: Leveraging all growth drivers to outperform IPM. Volume growth 2x higher than IPM, Pricing 1.5x higher, and New Introductions 2.4x higher than IPM for MAT Sep’26 1.  Outperforming Chronic Business: Chronic + Semi Chronic contribution stands at 71.2% for Q2 FY27 against 67.7% in Q2 FY26, as per MAT Sep’261. Growth of Chronic + Semi Chronic is ~350 bps higher than company growth.  ANVISA GMP Certification: Company has received Good Manufacturing Practice (GMP) certification from Brazil’s National Health Surveillance Agency (ANVISA) for its manufacturing facility at Bhayla, Ahmedabad, covering both Oral Solid Dosage (OSD) and Women’s Hormone production lines. This milestone further strengthens CORONA’s manufacturing excellence towards its philosophy of ‘ONE WORLD ONE QUALITY’ 1: Pharmatrac MAT Sep’26 Commenting on the results, Mr. Nirav K. Mehta, Managing Director & CEO, CORONA Remedies Limited, said: “We are pleased to announce another quarter of strong, consistent growth. Revenue grew 22.2% year-on-year in Q2FY27 and 22% in H1FY27, ahead of our stated guidance. Our domestic business grew at 22.9%, well ahead of the Indian Pharmaceutical Market (IPM) growth of 12%, and our chronic portfolio grew at nearly twice the rate of its market segment. This outperformance reflects our disciplined execution and consistent focus on our long-term strategy. We remain committed to strengthening our core therapies, building powerful brands, driving operational excellence and investing in capabilities that will support our future growth. The Indian pharmaceutical industry is underpinned by strong structural demand drivers. Backed by our diversified portfolio, established brands, expanding market reach and experienced leadership team, we are well positioned to capitalise on these opportunities and sustain our growth momentum.” About CORONA Remedies Limited Founded in 2004, CORONA Remedies Limited is an India-focused pharmaceutical company engaged in the development, manufacturing, and marketing of products across key therapeutic areas, including Women’s Healthcare, Cardio-Diabetes, Pain Management, and Urology. The company has established a strong presence in the Indian pharmaceutical market through its focus on scientific expertise, brand building, manufacturing excellence, and quality-driven operations. Its manufacturing facilities and research capabilities support its commitment to delivering high-quality healthcare solutions. Disclaimer: Certain statements contained in this document may be statements of future expectations and other forward-looking statements that are based on management ‘s current view and assumptions and involve known and unknown risks and uncertainties that could cause actual results, performance or events to di(cid:431)er materially from those expressed or implied in such statements. None of CORONA Remedies Limited or any of its a(cid:431)iliates, advisors or representatives shall have any liability whatsoever (in negligence or otherwise) for any loss howsoever arising from any use of this document or its content or otherwise arising in connection with this document. This document does not constitute an o(cid:431)er or invitation to purchase or subscribe for any shares and neither it nor any part of it shall form the basis of or be relied upon in connection with any contract or commitment whatsoever. For further information please contact Company Investor Relations Advisors CORONA Remedies Limited Strategic Growth Advisors Pvt Ltd. CIN No: L24231GJ2004PLC044656 CIN No: U74140MH2010PTC204285 Chetna Dharajiya – Company Sagar Shro(cid:431) / Tanay Shah Secretary & Compliance O(cid:431)icer Email id: sagar.shro(cid:431)@sgapl.net / tanay.shah@sgapl.net Tel No: +91 98205 19303 / +91 98333 91899